Richard Eek

4.3k total citations · 1 hit paper
39 papers, 2.7k citations indexed

About

Richard Eek is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Richard Eek has authored 39 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Richard Eek's work include Multiple Myeloma Research and Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Richard Eek is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Richard Eek collaborates with scholars based in Australia, United States and China. Richard Eek's co-authors include José Baselga, Danny Rischin, A. Feyereislova, Jean‐Yves Douillard, Shinzoh Kudoh, Giuseppe Giaccone, Seiji Yano, Steven D. Averbuch, Takeshi Horai and Yutaka Nishiwaki and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Richard Eek

37 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 2.4k citations Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Eek Australia	9	2.1k	2.0k	652	326	165	39	2.7k
Annetta Krebs United States	8	2.0k 1.0×	1.9k 0.9×	723 1.1×	395 1.2×	124 0.8×	8	2.8k
Ichiro Takata Japan	12	2.3k 1.1×	2.7k 1.3×	795 1.2×	345 1.1×	314 1.9×	50	3.4k
Maximilian J. Hochmair Austria	27	2.2k 1.1×	2.1k 1.1×	731 1.1×	607 1.9×	110 0.7×	215	2.9k
Panos Fidias United States	25	1.7k 0.8×	1.8k 0.9×	925 1.4×	276 0.8×	269 1.6×	58	3.0k
Kathryn H. Brown United Kingdom	15	1.4k 0.7×	1.8k 0.9×	931 1.4×	460 1.4×	134 0.8×	30	2.4k
Alison Templeton United Kingdom	7	1.9k 0.9×	2.4k 1.2×	759 1.2×	681 2.1×	96 0.6×	14	2.9k
G. Robinet France	23	2.1k 1.0×	2.3k 1.1×	522 0.8×	325 1.0×	163 1.0×	110	3.0k
Marcelo Marotti United Kingdom	14	2.1k 1.0×	2.7k 1.4×	878 1.3×	747 2.3×	101 0.6×	29	3.2k
Katsuhiro Masago Japan	25	1.2k 0.6×	1.5k 0.8×	453 0.7×	324 1.0×	98 0.6×	119	2.1k
Francisco Robert United States	28	1.8k 0.9×	1.4k 0.7×	1.1k 1.7×	312 1.0×	290 1.8×	107	3.2k

Countries citing papers authored by Richard Eek

Since Specialization

Citations

This map shows the geographic impact of Richard Eek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Eek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Eek more than expected).

Fields of papers citing papers by Richard Eek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Eek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Eek. The network helps show where Richard Eek may publish in the future.

Co-authorship network of co-authors of Richard Eek

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Eek. A scholar is included among the top collaborators of Richard Eek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Eek. Richard Eek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotasek, Dusan, Morteza Aghmesheh, Thomas Yau, et al.. (2024). Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study. Cancer. 130(11). 1991–2002. 1 indexed citations

Frentzas, Sophia, G. Thomas Budd, Catherine Shannon, et al.. (2024). Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients. Cancer Research. 84(9_Supplement). PO1–4. 3 indexed citations

Fukuoka, Masahiro, Seiji Yano, Giuseppe Giaccone, et al.. (2023). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(6). 1162–1171. 7 indexed citations

Jackson, Justin, John Burston, Craig Underhill, et al.. (2023). SARS-CoV-2 Seroprevalence in a Cohort of International Travellers Returning to Rural Australia: Enablers and Barriers to Containment of COVID-19. Australian and New Zealand Journal of Public Health. 47(1). 100003–100003.

Burbury, Kate, Marliese Alexander, S.J. Harris, et al.. (2022). Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score.. Journal of Clinical Oncology. 40(16_suppl). 12116–12116. 1 indexed citations

Lu, Janice, Kevin Kalinsky, Debu Tripathy, et al.. (2022). Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology. 40(16_suppl). TPS1112–TPS1112. 5 indexed citations

Yau, Thomas, Rasha Cosman, Miranda A. Moore, et al.. (2021). 138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors. Annals of Oncology. 32. S1437–S1438. 2 indexed citations

Quach, Hang, Masa Lasica, Anna Kalff, et al.. (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. Journal of Clinical Oncology. 39(15_suppl). TPS8055–TPS8055. 4 indexed citations

Jamal, Sumayah, Adnan Nagrial, Anthony M. Joshua, & Richard Eek. (2020). 803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors. A480.2–A481. 1 indexed citations

10.

Kenealy, Melita, Mark Hertzberg, Kerry Taylor, et al.. (2018). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 104(4). 700–709. 13 indexed citations

11.

Ng, Chin Hin, Stephen B. Ting, William Ying Khee Hwang, et al.. (2018). A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML). Annals of Oncology. 29. viii371–viii371. 1 indexed citations

12.

Tam, Constantine S., Hang Quach, Andrew J. Nicol, et al.. (2017). BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma. Blood. 130. 1745–1745. 1 indexed citations

13.

Worth, Leon J., Senthil Lingaratnam, Anita Taylor, et al.. (2011). Use of risk stratification to guide ambulatory management of neutropenic fever. Internal Medicine Journal. 41(1b). 82–89. 24 indexed citations

14.

Harris, Kristin, Edward Chow, Liying Zhang, et al.. (2009). Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastases. European Journal of Cancer. 45(14). 2510–2518. 44 indexed citations

15.

Alam, Mahmood, et al.. (2008). Discriminating factors in treatment decisions for chemotherapy in elderly patients with colorectal cancer. Cancer Forum. 32(1). 22. 4 indexed citations

16.

Vorobiof, Daniel, et al.. (2004). First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study. The Breast. 13(3). 219–226. 35 indexed citations

17.

Vorobiof, Daniel, Bernardo L. Rapoport, C. Slabber, et al.. (2004). Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology. 22(14_suppl). 5091–5091. 3 indexed citations

18.

Fukuoka, Masahiro, Seiji Yano, Giuseppe Giaccone, et al.. (2003). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 21(12). 2237–2246. 2392 indexed citations breakdown →

19.

Eek, Richard & Carla I. Falkson. (1998). Extended Survival in 80 Patients With Operable, Locoregionally Recurrent Breast Cancer Treated With Chemotherapy. American Journal of Clinical Oncology. 21(5). 501–504. 4 indexed citations

20.

Eek, Richard & Geoffrey Falkson. (1997). The Low-Grade Lymphoproliferative Disorders. Oncology. 54(6). 441–458. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact